1. Home
  2. NTRA vs KVUE Comparison

NTRA vs KVUE Comparison

Compare NTRA & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$208.72

Market Cap

32.9B

Sector

Health Care

ML Signal

HOLD

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$18.75

Market Cap

33.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
KVUE
Founded
2003
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Specialty Chemicals
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
32.9B
33.1B
IPO Year
2015
2023

Fundamental Metrics

Financial Performance
Metric
NTRA
KVUE
Price
$208.72
$18.75
Analyst Decision
Strong Buy
Buy
Analyst Count
14
12
Target Price
$253.79
$19.58
AVG Volume (30 Days)
1.1M
62.1M
Earning Date
02-27-2026
02-17-2026
Dividend Yield
N/A
4.47%
EPS Growth
N/A
35.31
EPS
N/A
0.75
Revenue
$2,116,676,000.00
$15,006,000,000.00
Revenue This Year
$33.95
N/A
Revenue Next Year
$16.72
$2.72
P/E Ratio
N/A
$24.81
Revenue Growth
38.17
N/A
52 Week Low
$125.38
$14.02
52 Week High
$256.36
$25.17

Technical Indicators

Market Signals
Indicator
NTRA
KVUE
Relative Strength Index (RSI) 35.85 74.70
Support Level $203.86 $17.96
Resistance Level $213.96 $18.97
Average True Range (ATR) 8.54 0.37
MACD -2.07 0.10
Stochastic Oscillator 23.88 84.96

Price Performance

Historical Comparison
NTRA
KVUE

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.

Share on Social Networks: